Citigroup Inc Brooklyn Immuno Therapeutics, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.23 - $0.71 $109 - $336	-474 Reduced 34.88%	885 $0
Q2 2022 Aug 10, 2022	SELL	$0.48 - $2.03 $551 - $2,330	-1,148 Reduced 45.79%	1,359 $1,000
Q1 2022 May 12, 2022	SELL	$1.76 - $4.84 $12,196 - $33,541	-6,930 Reduced 73.43%	2,507 $5,000
Q4 2021 Feb 10, 2022	BUY	$4.17 - $9.79 $23,748 - $55,754	5,695 Added 152.19%	9,437 $39,000
Q3 2021 Nov 10, 2021	BUY	$8.86 - $17.05 $33,154 - $63,801	3,742 New	3,742 $35,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.